Current Partnering makes available deals of significance to the life sciences industry for immediate purchase. All Dealdocs include the full contract, as submitted to the SEC.
Browse Dealdocs: Partnering below.
If you cannot find what you are looking for explore our Deals on demand service or contact us to find out how we can assist you in finding what you require.
Licensing agreement for Folate Binding Protein-E39 (FBP) targeted vaccine
Publication date: October 2011 | Price: from $150
Available Formats: PDF
Licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 (FBP) targeted vaccine to prevent recurrence in gynecological cancers more »
Collaborative R&D and commercialisation agreement for tivozanib
Publication date: February 2011 | Price: from $150
Available Formats: PDF
Astellas – Aveo Pharmaceuticals: Worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers more »
